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tus, greater work-related impairments, and increased health care resource use.
Given the additional burden of this comorbidity, the management of dyspepsia
among patients with AF should be a greater area of focus.
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OBJECTIVES: To analyse the association between Health Related Quality of Life
(HRQoL) and age, in hypertensive patients and the correlation between HRQoL
reported by patients and evaluated by their doctors. METHODS: Observational,
cross-sectional, multi-centre study, in Primary and Specialised Care. Inclusion of
5,031 hypertensive patients, selected by quotes according to three age groups (65,
65-79,  80 years) was planned. Selection criteria were: patients whose age was
over 18, diagnosed as having hypertension at least one year before inclusion and
attended a follow-up visit. Information related to hypertension, basic socio-demo-
graphic and clinical data, the self-administered specific questionnaire MINICHAL
for the evaluation of HRQoL (higher scores indicative of lower HRQoL), and a visual
analogue scale (VAS) for the general evaluation of HRQoL (higher scores indicative
of higher HRQoL) by patients and doctors, were recorded. Data of 4,346 eligible
patients were included. HRQoL-age correlation was analysed by Spearman’s-rho,
differences among age groups by Kruskal-Wallis and patient/doctor agreement by
the intraclass correlation coefficient (ICC). RESULTS: Mean age (SD) was
68.35(12.60). 38.1% of patients were under 65, 36.9% between 65 and 80 and 25.0%
were over 80 years old. 54.5% were men. Mean time since diagnosis was 10.33(7.68)
years. 34.2% had a family history of high blood pressure. Mean scores in MINICHAL
were: State of Mind dimension 8.07(5.83), Somatic Manifestations dimension
3.24(3.06). Worsening of both dimensions was found when comparing groups of
higher age (p0.001) as well as significant moderate correlations of both dimen-
sions with age (0.335, p0.001; 0.397 p0.001). Mean(SD) VAS score for doctors’
evaluation was 66.84(15.82) and 63.93(18.46) that of patients; ICC for agreement was
0.697 (0.672, 0.687 and 0.663 by age groups). CONCLUSIONS: An impact of age on
HRQoL worsening is evidenced. Patient/doctor agreement in the evaluation of
HRQoL is adequate; however doctors trend to overestimate the HRQoL of patients.
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OBJECTIVES: To determine the health related quality of life (HRQOL) of patients
with heart failure (HF) hospitalized in the Canary Islands and to estimate their
utilities by analyzing the influence of sociodemographic and clinical factors such
as gender or severity according to New York Heart Association (NYHA) classifica-
tion. A secondary objective is to obtain utilities to be used in an economic model to
evaluate a cardiac device. METHODS: Descriptive analysis within a prospective
observational multicenter study of a cohort of patients with HF admitted to cardi-
ology or internal medicine units at several hospitals in the Canary Islands, Spain.
HRQOL was assessed using the EQ-5D questionnaire among others. Utility was
estimated for the entire sample and for subgroups of patients, using the Spanish
tariffs VAS (visual analog scale) and TTO (time trade-off). RESULTS:We present the
results of a sample of 176 patients enrolled so far (51% male, mean age 74 years).
Average utility (SD) of the entire sample is 0.5297 (0.2107) (VAS rate). Women re-
ported poorer HRQOL than men (0.5182 vs. 0.5421); HRQOL is lower in health states
of lower functional capacity: 0.6400 in patients with NYHA-I and 0.4491 in patients
with NYHA-III. CONCLUSIONS: Differences between sub-groups and overall low
HRQOL were observed, possibly due to the hospitalization of surveyed patients.
These local findings coincide with the international literature and may be useful
for developing the economic model.
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OBJECTIVES: To compare work productivity impairment between Russian patients
with those in the 5EU and US and assess whether conditions have similar impact
across these geographies.METHODS:The study included data from the 2011 Russia
(N10,039), US (N75,000), and 5EU (N 57,512) National Health and Wellness
Survey, a survey representative of urban adults in Russia and total adult popula-
tions of the US and each 5EU country. Respondents self-reported physician diag-
nosis of type 2 diabetes (T2D) and cardiovascular (CV) conditions, as well as their
height and weight used to calculate obesity (BMI30). Work productivity impair-
ment and impairment in non-work activities was assessed with the Work Produc-
tivity and Activity Impairment (WPAI) questionnaire. Two-way ANOVAs tested for
differences in work productivity impairment by geography and condition.
RESULTS: There were regional differences in mean health-related work impair-
ment, with Russia the highest (22.6%), followed by 5EU (19.4%) and US (14.9%;
p0.001). Collapsing across geographies, obesity, T2D, and CV conditions were
each associated with more impaired work productivity (all ps0.01), but the mag-
nitude of the decrement associated with each disease depended on region (all
ps0.01). The incremental work productivity loss associated with obesity was
smallest in Russia (1.5%), compared with 5EU (3.9%) and US (2.7%). T2D patients in
Russia and 5EU experienced similar incremental work productivity impairment
(8.5%), while US T2D patients showed a difference of 5.0%. Similarly, Russians with
CV conditions were more impaired than in 5EU and US when compared with
non-CV patients (8.1% vs. 7.1% and 4.4%, respectively). CONCLUSIONS: Russians
have greater health-related work impairment than adults in US and 5EU. The in-
cremental burden of obesity, T2D, and CV conditions in Russia appears to differ
from the US and 5EU, being relatively small for obesity but greater for T2D and CV
conditions. These differences highlight the importance of country-specific infor-
mation for these markets.
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Anticoagulants are recommended for stroke prevention in atrial fibrillation (AF),
unfortunatly they also increase the risk of bleeding. For this reason, physicians face
benefit-risk trade-offs when prescribing anticoagulants to AF patients. Although
the unmet medical need for safer anticoagulants has been documented, the actual
patients and physicians preferences for outcomes associated with anticoagulants
are yet to be documented. OBJECTIVES: To quantify Japanese patients and physi-
cians preferences for benefits and risks associated with the use of anticoagulants in
AF and to enable cross-patient and physician comparison.METHODS: Patients45
years old with a self-reported physician diagnosis of AF, and board-certified inter-
nists, cardiologists, neurologists and neurosurgeons currently treating AF patients
were invited to complete a web-enabled, choice-format conjoint survey that in-
cluded a series of trade-off questions. Each trade-off question included a pair of
hypothetical anticoagulants defined by therapy-induced changes in the risk of
stroke, myocardial infarction, embolism, and bleeding. In addition, respondents
were asked to revisit their anticoagulant choice based on the risk of all-cause death
and on the monitoring requirement. Patients were asked to choose anticoagulants
for themselves, while physicians chose anticoagulants for virtual patients. Ran-
dom-parameters logit was used to estimate a relative preference weight for the risk
of each event based on respondents’ choices in the trade-off questions. RESULTS:
A total of 152 patients and 164 physicians completed the survey. Overall patients
and physicians considered all-cause death to be the least desirable outcome.
Among non-fatal outcomes, patients considered the risk of disabling stroke to be
2.6 times more important than extra-cranial major bleeding and 16 times more
important than non-major clinically relevant bleeding compared to 1 time and 2.7
times for physicians. CONCLUSIONS: Japanese patients and physicians have dif-
ferent preferences for non-fatal outcomes associated with anticoagulants, with
patients willing to tolerate a greater risk of bleeding for stroke prevention than
physicians.
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Although effective for stroke prevention in atrial fibrillation (AF), anticoagulants
increase the risk of bleeding. The relative importance of benefits and risks associ-
ated with anticoagulants is influenced by various factors and has mostly been
documented only in physicians. OBJECTIVES: To identify patients characteristics
influencing the relative importance of non-fatal outcomes associated with
anticoagulants. METHODS: Data from a choice-format conjoint survey asking AF
patients to choose between hypothetical anticoagulants were used to estimate
importance weights for non-fatal outcomes associated with anticoagulants. The
influence of patients characteristics was tested by evaluating the significance of
interactions between importance weights and age, gender, prior use of anticoagu-
lants, personal history of stroke, family history of stroke and personal or family
history of bleeding. RESULTS: A total of 152 patients completed the survey. Only
two patients characteristics significantly influenced the relative importance of
non-fatal outcomes associated with anticoagulants. Overall, the least desirable
non-fatal outcome was disabling stroke. Using disabling stroke as a reference,
patients characteristics such as prior use of anticoagulants increased the relative
importance of non-disabling stroke by 48%, major extra-cranial bleeding by 12%
and non-major clinically relevant bleeding by 82%. On the other hand, personal or
family history of bleeding increased the relative importance of major extra-cranial
bleeding by 19% and non-major clinically relevant bleeding by 34% while decreas-
ing the relative importance of non-disabling stroke by 15%. CONCLUSIONS: This
study documents the impact of patients prior experience on relative importance of
non-fatal outcomes associated with anticoagulants. Proper explanation of the ben-
efits and risks of anticoagulants may play a role in patients understanding and
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